References
Sonnefield ST, Waldo DR, Lemieux JA. et al. Projections of national health expenditures through the year 2000. Health Care Finane Rev 1991: 13: 1–27
Oye RD, Bellamy PE. Patterns of resources consumption in medical intensive care. Chest 1991; 99: 685–9
Wagner DP, Wineland TD, Knaus WA. The hidden cost of consumption in an intensive care unit. Health Care Finance Rev 1983; 5: 81–6
Rapoport J, Teres D, Lemeshow S, et al. Explaining variability or cost using a severity–of–illness measure for ICU patients. Med Care 1990: 28: 338–48
Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985: 13: 818–29
Le Gall JR, Loirat P, Alperovitch A, et al. A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12: 975–7
Teres D, Lemeshow S. Evaluating the severity of illness in critically ill patients. In: Shoemaker WE, Abraham E, editors. Diagnostic methods in critical care: automated data collection and interpretation. New York: Marcel Dekker, Inc., 1981: 1–17
Udvarhelyi IS, Colditz GA, Rai A, et al. Cost–effectiveness and cost–benefit analysis in the medical literature. Ann Intern Med 1992: 116: 238–44
Bottman JL, Wertheimer AI, Zaske D, et al. Individualizing gentamicin dosage regimens in burn patients with gram–negative septicemia: a cost–benefit analysis. J Pharmaceutical Sci 1979: 68: 267–72
Franklin C, Nightingale S, Mamdani B. A randomized comparison of nifedipine and sodium nitroprusside in severe hypertension. Chest 1986: 90: 500–3
Kreis DJ, Augestein D, Martinez O, et al. A prospective randomized study of moxalactam versus gentamicin and clindamycin in penetrating abdominal trauma. Surg Gynecol Obstet 1986: 163: 1–4
Laffel GL, Fineberg HV, Braunwald E, A cost–effective model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987: 10 Suppl. B: 79b–9Ob
Chapekis AT, Burek K, Topol EJ. The cost: benelit ratio for accute intervention for myocardial infarction: results of a prospective, matched pair analysis. Am Heart J 1989: 118: 878–82
Dunagan WC, Woodward RS, Medoff G. et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989; 87: 253–9
Fenn P, Gray AM, McGuire A, The cost–effectiveness of thrombolytic therapy following acute myocardial infarction. Br J Clin Pharmacol 1991: 45: 181–4
Schulman KA, Glick HA, Rubin H, et al. Cost–effectiveness of HA-1A monoclonal antibody for gram–negative sepsis. JAMA 1991; 266: 2466–71
Smedstad KG, Beattie WS, Blair WS. et al. Postoperative pain relief and hospital stay after total esophagectomy. Clin J Pain 1992: 8: 149–53
Levin LA, Jansson B. Cost–effectiveness of thrombolysis–a randomized study of intravennus rt–PA in suspected myocardial infarction. Eur Heart J 1992; 13: 2–8
Chalfin DB, Holbein EB, Fein AM, et al. Cost–effectiveness of monoclonal antibodies to Gram–negative endoxotin in the treatment of Gram–negative sepsis in ICU patients. JAMA 1993; 269: 249–54
Reeder GS, Baily KR, Gersh BJ, et al. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Clin Proc 1994: 69: 5–12
Weinstein MC, Slawn WB, Foundations of cost–effectiveness analysis for health and medical practices. N Engl J Med 1977: 269: 116–21
AIMS Trial Study Group. Long–term effects of intravenous anistreplase in a cute myocardial infarction: final report of the AIMS study. Lancet 1990: 335: 427–31
Feller I, Tholen D, Cornell RG. Improvements in bum care 1965 to 1979. JAMA 1980; 244: 2074–8
Lemeshow S, Teres D. Avrunin JS. et al. Refining intensive care unit outcome prediction by using a changing probabilities of mortality. Crit Care Med 1988: 16: 470–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clifton, G.D., Blumenschein, K. The Use of Pharmaceuticals in Critical Care. Pharmacoeconomics 7, 388–392 (1995). https://doi.org/10.2165/00019053-199507050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199507050-00003